Scandinavian ChemoTech
Scandinavian ChemoTech AB (publ) publishes Interim Report Q1 2025
REG
First quarter 2025
- Net sales amounted to 2 472 KSEK (1 345)
- Profit/loss after financial items amounted to -3 322 KSEK (-3 203)
- Earnings per share amounted to -0,14 SEK (-0,18)
- Cash flow from operating activities amounted to -1 239 KSEK (-4 853)
- All orders were delivered by the end of the period
Events during the reporting period
- ChemoTech implements management changes to reduce costs.
- ChemoTech's Animal Care operations showed positive cashflow for 2024 in separate reporting.
- ChemoTech restructures loans and doubles the duration to 12 months.
- ChemoTech secures a new order and expands Animal Care Operations through global collaboration in equine oncology
Events after the reporting period
- ChemoTech starts 2025 strong with Q1 order intake exceeding USD 230,000.
- Animal Care expands U.S. presence with new partnership, securing an order of appr. USD 66,000.
- ChemoTech's Animal Care celebrates record-breaking month with order intake of 200,000 USD in April.
This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 06-05-2025 08:30 CET.
| Datum | 2025-05-06, kl 08:30 |
| Källa | Cision |
Skapa konto direkt med BankID hos Skilling så får du tillgång till tusentals finansmarknader inom valuta, aktier, krypto och mycket mer. Välj bland 1200+ CFD-instrument över 7 tillgångsklasser till konkurrenskraftiga priser. Skilling erbjuder också en kapitalförsäkring.
CFD är komplexa instrument och har en hög risk att förlora pengar snabbt på grund av hävstång. 77% av icke-professionella kunder förlorar pengar när de handlar med CFD med denna leverantör.